MX2022002451A - Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos. - Google Patents

Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos.

Info

Publication number
MX2022002451A
MX2022002451A MX2022002451A MX2022002451A MX2022002451A MX 2022002451 A MX2022002451 A MX 2022002451A MX 2022002451 A MX2022002451 A MX 2022002451A MX 2022002451 A MX2022002451 A MX 2022002451A MX 2022002451 A MX2022002451 A MX 2022002451A
Authority
MX
Mexico
Prior art keywords
subject
methods
disease
cln2 disease
cln2
Prior art date
Application number
MX2022002451A
Other languages
English (en)
Inventor
David Jacoby
Joshua Henshaw
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2022002451A publication Critical patent/MX2022002451A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)

Abstract

Se proporcionan aquí métodos para tratar la enfermedad de lipofuscinosis neuronal ceroidea (CLN2) en un sujeto menor de 3 años de edad. En modalidades ejemplares, el método comprende administrar al sujeto una formulación que comprende tripeptidil peptidasa-1 humana recombinante (rhTPP1) en una cantidad efectiva para tratar la enfermedad CLN2 en el sujeto. También se proporcionan métodos para retrasar la aparición de la enfermedad CLN2, o un síntoma de la misma, en un sujeto menor de 3 años. En modalidades ejemplares, el método comprende administrar al sujeto una formulación que comprende tripeptidil peptidasa-1 humana recombinante (rhTPP1) en una cantidad efectiva para retrasar la aparición de la enfermedad o síntoma de CLN2 en el sujeto.
MX2022002451A 2019-08-29 2020-08-31 Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos. MX2022002451A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893535P 2019-08-29 2019-08-29
PCT/US2020/048704 WO2021042020A1 (en) 2019-08-29 2020-08-31 Methods for treating cln2 disease in pediatric subjects

Publications (1)

Publication Number Publication Date
MX2022002451A true MX2022002451A (es) 2022-06-02

Family

ID=72470612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002451A MX2022002451A (es) 2019-08-29 2020-08-31 Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos.

Country Status (15)

Country Link
US (1) US20220273775A1 (es)
EP (1) EP4021575A1 (es)
JP (1) JP2022546042A (es)
KR (1) KR20220054375A (es)
CN (1) CN114828960A (es)
AR (1) AR119871A1 (es)
AU (1) AU2020336984A1 (es)
BR (1) BR112022003598A2 (es)
CA (1) CA3152521A1 (es)
CL (1) CL2022000496A1 (es)
HR (1) HRP20220370A1 (es)
IL (1) IL290763A (es)
MX (1) MX2022002451A (es)
TW (1) TW202122106A (es)
WO (1) WO2021042020A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302685B1 (en) 1997-09-16 2001-10-16 University Of Medicine And Dentistry Of New Jersey Human lysosomal protein and methods of its use
US20020006400A1 (en) * 2000-05-11 2002-01-17 Peter Lobel Recombinant human CLN2 protein and methods of its production and use
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
CN108601771B (zh) * 2015-10-23 2023-02-21 衣阿华大学研究基金会 使用基因疗法以推迟疾病发生和发展同时提供认知保护来治疗神经变性疾病的方法
MX2021005517A (es) * 2018-11-14 2021-06-18 Regenxbio Inc Terapia genica para lipofuscinosis neuronal ceroidea.

Also Published As

Publication number Publication date
HRP20220370A1 (hr) 2022-09-16
EP4021575A1 (en) 2022-07-06
CL2022000496A1 (es) 2022-10-21
US20220273775A1 (en) 2022-09-01
AR119871A1 (es) 2022-01-19
CN114828960A (zh) 2022-07-29
WO2021042020A1 (en) 2021-03-04
TW202122106A (zh) 2021-06-16
IL290763A (en) 2022-04-01
BR112022003598A2 (pt) 2022-05-24
KR20220054375A (ko) 2022-05-02
CA3152521A1 (en) 2021-03-04
AU2020336984A1 (en) 2022-03-10
JP2022546042A (ja) 2022-11-02

Similar Documents

Publication Publication Date Title
WO2020047462A3 (en) Methods of treating aging-related disorders
Karst et al. Pressure pain threshold and needle acupuncture in chronic tension-type headache–a double-blind placebo-controlled study
EP4327873A3 (en) Tpp1 formulations and methods for treating cln2 disease
Gamit et al. The effect of stretching exercise on primary dysmenorrhea in adult girls
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
WO2008133928A3 (en) Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
EA201891507A1 (ru) Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
WO2005009217A3 (en) Diagnosis of pre-cancerous conditions using pcdgf agents
MX2022002451A (es) Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos.
Boyaci et al. Comparison of the short-term effectiveness of short-wave diathermy treatment in patients with carpal tunnel syndrome: a randomized controlled trial
MX367580B (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer.
Kawecki et al. Computerized planimetry evaluation of hyperbaric oxygen therapy in the treatment of diabetic foot
WO2016081296A3 (en) Topical medicament for skin and mucosal injuries associated with epidermolisis bullosa
MX2020005809A (es) Composicion topica oftalmica para tratar enfermedades del segmento posterior del ojo.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
WO2020061067A8 (en) Compositions and methods for treating bone injury
ELsehrawy et al. Extracorporeal shock wave therapy versus low-level laser therapy in the management of chronic plantar fasciitis
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
De la Cruz-Torres Ultrasound-guided percutaneous neuromodulation in chronic lateral elbow pain